Skip to main content
Premium Trial:

Request an Annual Quote

Swift Bio Completes $7M Series B Financing

NEW YORK (GenomeWeb News) – Swift Biosciences today said it has completed a Series B financing round that raised $7 million.

Fletcher Spaght Ventures led the round and was joined by Renaissance Venture Capital Fund and Series A investors, including Mercury Fund, Michigan Accelerator Fund, and individuals.

"This funding will support the expansion of our sales and marketing programs, as well as accelerate new product introductions," Swift Bio's CEO David Olson said in a statement. "Our portfolio of creative, market-driven technologies continues to grow."

Peter Kleinhenz, a venture partner at Fletcher Spaght, is joining Ann Arbor, Mich.-based Swift Bio's board.

The company develops technologies for genomics and personalized medicine. Earlier this year, it entered the next-generation sequencing market with the launch of its Accel-NGS sample preparation products.

Late in 2012, it licensed its myT Primer technology to Vela Diagnostics. In 2010, the company raised $3 million in a Series A round, and added $2.4 million in follow-on financing in early 2012, as PCR Insider reported at the time.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.